At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Omalizumabdrug
Likely dose
Omalizumab 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria
In Brief
A Phase 4 clinical trial evaluating Omalizumab for Chronic Urticaria. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study looks at changes in cell proteins in people with chronic hives treated with omalizumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Urticaria
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartApr 2013
Primary CompletionApr 2016
Study CompletionOct 2017
TodayJul 2026
First PostedOct 5, 2012
Enrollment StartApr 1, 2013
Primary CompletionApr 1, 2016
Study CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 13.7 years ago
Interventions
Omalizumabdrug
Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.